These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37401759)

  • 1. The role of B cells in immune cell activation in polycystic ovary syndrome.
    Ascani A; Torstensson S; Risal S; Lu H; Eriksson G; Li C; Teschl S; Menezes J; Sandor K; Ohlsson C; Svensson CI; Karlsson MCI; Stradner MH; Obermayer-Pietsch B; Stener-Victorin E
    Elife; 2023 Jul; 12():. PubMed ID: 37401759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurokinin 3 Receptor Antagonism Ameliorates Key Metabolic Features in a Hyperandrogenic PCOS Mouse Model.
    Sucquart IE; Nagarkar R; Edwards MC; Rodriguez Paris V; Aflatounian A; Bertoldo MJ; Campbell RE; Gilchrist RB; Begg DP; Handelsman DJ; Padmanabhan V; Anderson RA; Walters KA
    Endocrinology; 2021 May; 162(5):. PubMed ID: 33522579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model.
    Xiong T; Rodriguez Paris V; Edwards MC; Hu Y; Cochran BJ; Rye KA; Ledger WL; Padmanabhan V; Handelsman DJ; Gilchrist RB; Walters KA
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E145-E158. PubMed ID: 35658542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of DHT-Induced Hyperandrogenism on the Pro-Inflammatory Cytokines in a Rat Model of Polycystic Ovary Morphology.
    Krishnan A; Muthusami S; Periyasamy L; Stanley JA; Gopalakrishnan V; Ramachandran I
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32120970
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome.
    Dilaver N; Pellatt L; Jameson E; Ogunjimi M; Bano G; Homburg R; D Mason H; Rice S
    Hum Reprod; 2019 Dec; 34(12):2467-2479. PubMed ID: 31735954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism.
    Froment P; Plotton I; Giulivi C; Fabre S; Khoueiry R; Mourad NI; Horman S; Ramé C; Rouillon C; Grandhaye J; Bigot Y; Chevaleyre C; Le Guevel R; Mallegol P; Andriantsitohaina R; Guerif F; Tamburini J; Viollet B; Foretz M; Dupont J
    Hum Reprod; 2022 May; 37(6):1207-1228. PubMed ID: 35459945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model.
    Aflatounian A; Edwards MC; Rodriguez Paris V; Bertoldo MJ; Desai R; Gilchrist RB; Ledger WL; Handelsman DJ; Walters KA
    J Endocrinol; 2020 Jun; 245(3):381-395. PubMed ID: 32229702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased uterine androgen receptor protein abundance results in implantation and mitochondrial defects in pregnant rats with hyperandrogenism and insulin resistance.
    Zhang Y; Hu M; Yang F; Zhang Y; Ma S; Zhang D; Wang X; Sferruzzi-Perri AN; Wu X; Brännström M; Shao LR; Billig H
    J Mol Med (Berl); 2021 Oct; 99(10):1427-1446. PubMed ID: 34180022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome.
    Xue P; Wang Z; Fu X; Wang J; Punchhi G; Wolfe A; Wu S
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30346398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derailed peripheral circadian genes in polycystic ovary syndrome patients alters peripheral conversion of androgens synthesis.
    Johnson BS; Krishna MB; Padmanabhan RA; Pillai SM; Jayakrishnan K; Laloraya M
    Hum Reprod; 2022 Jul; 37(8):1835-1855. PubMed ID: 35728080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperandrogenic Milieu Dysregulates the Expression of Insulin Signaling Factors and Glucose Transporters in the Endometrium of Patients With Polycystic Ovary Syndrome.
    Lee MH; Yoon JA; Kim HR; Kim YS; Lyu SW; Lee BS; Song H; Choi DH
    Reprod Sci; 2020 Aug; 27(8):1637-1647. PubMed ID: 32430710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    Caldwell ASL; Edwards MC; Desai R; Jimenez M; Gilchrist RB; Handelsman DJ; Walters KA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):E3334-E3343. PubMed ID: 28320971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization.
    Caldwell AS; Eid S; Kay CR; Jimenez M; McMahon AC; Desai R; Allan CM; Smith JT; Handelsman DJ; Walters KA
    Endocrinology; 2015 Apr; 156(4):1441-52. PubMed ID: 25643156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Action in Adipose Tissue and the Brain are Key Mediators in the Development of PCOS Traits in a Mouse Model.
    Cox MJ; Edwards MC; Rodriguez Paris V; Aflatounian A; Ledger WL; Gilchrist RB; Padmanabhan V; Handelsman DJ; Walters KA
    Endocrinology; 2020 Jul; 161(7):. PubMed ID: 32301482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated reactive oxygen species production in pregnant rats that mimic the clinical features of polycystic ovary syndrome.
    Zhang Y; Zhao W; Xu H; Hu M; Guo X; Jia W; Liu G; Li J; Cui P; Lager S; Sferruzzi-Perri AN; Li W; Wu XK; Han Y; Brännström M; Shao LR; Billig H
    J Physiol; 2019 Aug; 597(15):3927-3950. PubMed ID: 31206177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model.
    Benrick A; Chanclón B; Micallef P; Wu Y; Hadi L; Shelton JM; Stener-Victorin E; Wernstedt Asterholm I
    Proc Natl Acad Sci U S A; 2017 Aug; 114(34):E7187-E7196. PubMed ID: 28790184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pigment epithelium-derived factor (PEDF) negates hyperandrogenic PCOS features.
    Miller I; Bar-Joseph H; Nemerovsky L; Ben-Ami I; Shalgi R
    J Endocrinol; 2020 May; 245(2):291-300. PubMed ID: 32171180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive and metabolic phenotype of a mouse model of PCOS.
    van Houten EL; Kramer P; McLuskey A; Karels B; Themmen AP; Visser JA
    Endocrinology; 2012 Jun; 153(6):2861-9. PubMed ID: 22334715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.